As of November 10, 2026, Azora Therapeutics, Inc. (DE) is a publicly traded company (Nasdaq: AZR). The largest insider holding is Matt Davidson, the chief executive and president, with 923,743 shares (35.2% of shares outstanding), per Form 4 of November 4, 2026. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13G/A, July 1, 2026).
Is this your company?
About to sign with, pay or invest in Azora Therapeutics, Inc. (DE)? See the free Snapshot first.
Free to see. No signup.
Is Azora Therapeutics, Inc. (DE) a real, registered company?
- Azora Therapeutics, Inc. files with the SEC under CIK 1513525 (its SEC filings).
- Its shares are listed under the ticker AZR on Nasdaq (also ADIL) (SEC company record).
- Incorporated in Delaware; business address in Charlottesville, Virginia, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ADIAL PHARMACEUTICALS, INC. in our court records and SEC 8-K records (as of 2026-11-10).
- Leadership changes: the latest reported is Aida Habtezion, Director (Form 8-K filed 2026-11-09). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Coastlands Capital LP (filed 2026-07-01).
Who are Azora Therapeutics, Inc. (DE)'s owners and officers?
Azora Therapeutics, Inc. (DE): incorporated in Delaware; business address in Charlottesville, Virginia; industry Pharmaceutical Preparations (Form D, 2026-11-09).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-12-03)
- : Executive Officer (Form D, 2025-12-03)
- : Director (Form D, 2025-12-03)
- : Director (Form D, 2025-12-03)
- : Director (Form D, 2025-12-03)
- : Director (Form D, 2025-12-03)
- : Executive Officer, Director (Form D, 2025-12-03)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-03 | Coastlands Capital LP | 4.99% |
| Schedule 13G/A, 2026-07-01 | Coastlands Capital LP | 14.22% |
| Schedule 13G, 2026-06-24 | Coastlands Capital LP | 9.98% |
| Schedule 13G/A, 2026-05-15 | Armistice Capital, LLC | 4.99% |
| Schedule 13G, 2026-02-18 | Armistice Capital, LLC | 9.99% |
Want the whole picture on Azora Therapeutics, Inc. (DE)?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Azora Therapeutics, Inc. (DE): verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Azora Therapeutics, Inc. (DE) covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
23 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-11-09 | Aida Habtezion | Director | appointed | |
| Form 8-K, 2026-10-28 | Matthew Davidson | President and Chief Executive Officer | appointed | |
| Form 8-K, 2026-10-28 | Celia Economides | Chief Financial Officer | appointed | |
| Form 8-K, 2026-10-28 | Julie Saiki | Chief Strategy Officer | appointed | |
| Form 8-K, 2026-06-11 | Tony Goodman | departed | ||
| Form 8-K, 2026-06-11 | Matt Davidson | Chief Development Officer | appointed |
Which insiders own Azora Therapeutics, Inc. (DE) shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 923,743 shares (35.2% of shares outstanding), 819,018 held directly and 104,725 indirectly (Form 4, 2026-11-04).
- , the chief strategy officer: 761,636 shares (29.0% of shares outstanding) (Form 4, 2026-11-04).
- Coastlands Capital LP, a 10% owner: 388,308 shares (14.8% of shares outstanding), held indirectly through By Coastlands Capital LP (Form 4, 2026-11-03).
- , the chief executive and a director: 40,417 shares (1.5% of shares outstanding) (Form 4, 2026-04-09).
- , the chief operating officer and a director: 26,523 shares (1.0% of shares outstanding) (Form 4, 2026-04-09).
Shares outstanding: 2,625,890 as of 2026-08-12, from the company's latest SEC cover page.
How much has Azora Therapeutics, Inc. (DE) raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-12-03 | $4.29M | $4.29M |
| Form D, 2025-05-14 | $4.82M | $4.82M |
| Form D, 2024-03-14 | $288K | $288K |
| Form D, 2023-10-26 | $4M | $4M |
| Form D, 2023-06-05 | $53K | $3.05M |
| Form D, 2023-03-06 | $62K | $62K |
Latest IPO step: Azora Therapeutics, Inc. (DE) amended its IPO registration (S-1/A, 2025-06-13).
IPO filings: S-1/A, 2025-06-13, S-1, 2025-06-06, S-1, 2024-12-20; ticker ADIL on Nasdaq Capital Market.
Acquisitions reported on Form 8-K, Item 2.01: acquired Azora Therapeutics, Inc. (2026-06-11).
Keep reading
More on Azora Therapeutics, Inc. (DE) and the records around it.
Azora Therapeutics, Inc. (DE) elsewhere on the record
- Leadership changes Nov 2026
- Acquisition Jun 2026
- Form D filing Dec 2025
- Form D filing May 2025
Companies that share a holder
- Coastlands Capital LP also filed stake reports on 15 other companies: Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/azora-therapeutics